Bayer Healthcare LLC  
Attention: Joanna Fleming  
Associate Director, Regulatory Affairs  
100 Bayer Blvd  
Whippany, NJ 07981

Dear Ms. Fleming:

Please refer to your Supplemental New Drug Application (sNDA) dated March 31, 2016, received April 1, 2016, and your amendments, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for MiraLAX (polyethylene glycol 3350), powder for solution.

This “Prior Approval” supplement provides for the following changes:

- Adds a 20-count carton stock keeping unit (contains 20 individual packets (sachets)) and associated labeling to be marketed with either of two alternative 20-count package designs
- Replaces the individual packet (sachet) descriptor “NeatPAX” with a new descriptor, “Mix-In Pax”
- Revises graphic design located on each carton’s principal display panel (PDP) and side panels
- Includes two alternative graphic designs for the approved 10-count stock keeping unit labeling

We have completed our review of this application, as amended. It is approved, effective on the date of this letter, for use as recommended in the agreed-upon labeling text, and with the minor editorial revision listed below:

Remove [text removed] that was proposed for the 10- and 20-count stock keeping units.

**LABELING**

Submit final printed labeling identical to the following labeling received on August 17, 2016:

- 1-dose immediate container (sachet) label
- 1-dose “Not For Individual Sale” immediate container (sachet) label
- 1-dose “Sample – Not for Sale” immediate container (sachet) label
- 10-count carton label
- 20-count carton label

Reference ID: 3993160
• 24- and 50-count carton labels

The final printed labeling should be submitted electronically according to the guidance for industry titled “Providing Regulatory Submissions in Electronic Format – Human Pharmaceutical Product Applications and Related Submissions Using the eCTD Specifications (June 2008).” Alternatively, you may submit 12 paper copies, with 6 of the copies individually mounted on heavy-weight paper or similar material. For administrative purposes, designate this submission “Final Printed Labeling for approved NDA 022015/S-025.” Approval of this submission by FDA is not required before the labeling is used.

**DRUG REGISTRATION AND LISTING**

All drug establishment registration and drug listing information is to be submitted to FDA electronically, via the FDA automated system for processing structured product labeling (SPL) files (eLIST). At the time that you submit your final printed labeling (FPL), the content of labeling (Drug Facts) should be submitted in SPL format as described at [http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm](http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm). Information on submitting SPL files using eLIST may be found in the guidance for industry titled “SPL Standard for Content of Labeling Technical Qs and As” at [http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM072392.pdf](http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM072392.pdf). In addition, representative container or carton labeling, whichever includes Drug Facts, (where differences exist only in the quantity of contents statement) should be submitted as a JPG file.

**REQUIRED PEDIATRIC ASSESSMENTS**

Under the Pediatric Research Equity Act (PREA) (21 U.S.C. 355c), all applications for new active ingredients, new indications, new dosage forms, new dosing regimens, or new routes of administration are required to contain an assessment of the safety and effectiveness of the product for the claimed indication(s) in pediatric patients unless this requirement is waived, deferred, or inapplicable.

Because none of these criteria apply to your application, you are exempt from this requirement.

**REPORTING REQUIREMENTS**

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).
If you have any questions, call Daniel Reed, Regulatory Project Manager, at (301) 796-2220.

Sincerely,

[See appended electronic signature page]

Karen Murry Mahoney, MD, FACE
Deputy Director
Division of Nonprescription Drug Products
Office of Drug Evaluation IV
Center for Drug Evaluation and Research

ENCLOSURE(S):
Carton and Container Labeling
This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

KAREN M MAHONEY
09/30/2016